On July 12, 2016, CytRx released the results of its Phase 3 clinical trial of aldoxorubicin. The results did not show any meaningful improvement compared to other commonly used cancer drugs. CytRx revealed that close to half of all patients in the Phase 3 trial were excluded from the data since the study was disturbed by a partial clinical hold in November 2014. Following this news, CytRx stock dropped from a previous close of $2.79 per share to a low of $0.75 per share during early morning trading on June 12, 2016.
If you purchased CytRx shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!cytr/lvnfh. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-cytrx-corporation-cytr-300297437.html
SOURCE Bronstein, Gewirtz & Grossman, LLC